This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delbaldo, C. Articles by Vassal, G. Search for Related Content PubMed PubMed Citation Articles by Delbaldo, C. Articles by Vassal, G.

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

Authors' Affiliations: ¹ Hospital Henri-Mondor, Créteil, France, ² EA3035, Institut Claudius-Regaud, Toulouse, France, ³ Pharmacology and New Treatment of Cancer, UPRES EA3535, ⁴ Mass Spectrometry Facility, and ⁵ Department of Medicine, Institut Gustave-Roussy, Villejuif, France, ⁶ Novartis Pharma, France, and ⁷ Centre Léon-Bérard, Lyon, France

Requests for reprints: Gilles Vassal, Pharmacology and New Treatment of Cancer, UPRES EA 3535, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. Phone: 33-14211-4947; Fax: 33-14211-5308; E-mail: gvassal{at}igr.fr.

Purpose: This study explored factors affecting the pharmacokinetic variability of imatinib and CGP 74588, and the pharmacokinetic-pharmacodynamic correlations in patients with advanced gastrointestinal stromal tumors.

Experimental Design: Thirty-five patients with advanced gastrointestinal stromal tumors received 400 mg of imatinib daily. Six blood samples were drawn: before intake, during 1- to 3- and 6- to 9-hour intervals after intake on day 1, and before intake on days 2, 30, and 60. Plasma imatinib and CGP 74588 concentrations were quantified by reverse-phase high-performance liquid chromatography coupled with tandem mass spectrometry, and analyzed by the population pharmacokinetic method (NONMEM program). The influence of 17 covariates on imatinib clearance (CL) and CGP 74588 clearance (CLM/fm) was studied. These covariates included clinical and biological variables and occasion (OCC = 0 for pharmacokinetic data corresponding to the first administration, or OCC = 1 for the day 30 or 60 administrations).

Results: The best regression formulas were: CL (L/h) = 7.97 (AAG/1.15)^–0.52, and CLM/fm (L/h) = 58.6 (AAG/1.15)^–0.60 x 0.55^OCC, with the plasma 1-acid glycoprotein (AAG) levels indicating that both clearance values decreased at a higher AAG level. A significant time-dependent decrease in CLM/fm was evidenced with a mean (+SD) CGP 74588/imatinib area under the curve (AUC) ratio of 0.25 (±0.07) at steady state, compared with 0.14 (±0.03) on day 1. Hematologic toxicity was correlated with pharmacokinetic variables: the correlation observed with the estimated unbound imatinib AUC at steady-state (r = 0.56, P < 0.001) was larger than that of the total imatinib AUC (r = 0.32, NS).

Conclusions: The plasma AAG levels influenced imatinib pharmacokinetics. A protein-binding phenomenon needs to be considered when exploring the correlations between pharmacokinetics and pharmacodynamics.

This article has been cited by other articles:

				G. D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C. D. Blanke, H. Joensuu, and M. von Mehren Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors J. Clin. Oncol., July 1, 2009; 27(19): 3141 - 3147. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, S. George, S. Bauer, and J. A. Fletcher Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies ASCO Educational Book, January 1, 2009; 2009(1): 694 - 699. [Abstract] [Full Text] [PDF]

				N. van Erp, H. Gelderblom, M. van Glabbeke, A. Van Oosterom, J. Verweij, H.-J. Guchelaar, M. Debiec-Rychter, B. Peng, J.-Y. Blay, and I. Judson Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC Clin. Cancer Res., December 15, 2008; 14(24): 8308 - 8313. [Abstract] [Full Text] [PDF]

				A. Petain, D. Kattygnarath, J. Azard, E. Chatelut, C. Delbaldo, B. Geoerger, M. Barrois, S. Seronie-Vivien, A. LeCesne, G. Vassal, et al. Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults Clin. Cancer Res., November 1, 2008; 14(21): 7102 - 7109. [Abstract] [Full Text] [PDF]

				R. K. Ramanathan, M. J. Egorin, C. H.M. Takimoto, S. C. Remick, J. H. Doroshow, P. A. LoRusso, D. L. Mulkerin, J. L. Grem, A. Hamilton, A. J. Murgo, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 563 - 569. [Abstract] [Full Text] [PDF]